Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Family Planning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Intend to deliver in the Labor and Delivery Unit at Ohio State University Wexner Medical Center, Grady Memorial Hospital or Emory University Midtown;~2. Are ≥18 years of age;~3. Speak English;~4. Intend to breastfeed, or express milk for their infant, for ≥6 months;~5. Do not want to become pregnant within the first 12 months after delivery;~6. Want to start use of DMPA immediately after delivery before discharge or no hormonal contraception immediately postpartum; AND~7. Intend to reside in Ohio or Georgia for the first 12 months after delivery.~   Exclusion Criteria:~8. Undiagnosed vaginal bleeding;~9. Known or suspected malignancy of breast;~10. Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease;~11. Liver dysfunction or disease; OR~12. Known hypersensitivity to Depo-Provera.~Women who enroll prenatally will need to rescreen following delivery to confirm their eligibility. Women enrolling after delivery or who are rescreening will need to meet criteria 2-12 above as well as the following eligibility criteria:~1. Are a postpartum patient in the Labor and Delivery Unit at OSUWMC, Grady Memorial Hospital or Emory University Midtown Hospital; AND~2. Have delivered a term, singleton infant of ≥2500 grams without any apparent health concerns.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
- Placebo arm (Type: PLACEBO_COMPARATOR): 0.9% sodium chloride injection provided within 48 hours of childbirth
- Open arm (Type: NO_INTERVENTION): No intervention provided

Based on this trial design, predict the completion outcome and termination type (if applicable).